$32.60
2.10% today
Nasdaq, Apr 04, 09:48 pm CET
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Praxis Precision Medicines Inc Target price 2025 - Analyst rating & recommendation

Praxis Precision Medicines Inc Classifications & Recommendation:

Buy
91%
Sell
9%

Praxis Precision Medicines Inc Price Target

Target Price $99.27
Price $33.30
Potential
Number of Estimates 11
11 Analysts have issued a price target Praxis Precision Medicines Inc 2026 . The average Praxis Precision Medicines Inc target price is $99.27. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend Praxis Precision Medicines Inc to buy, 0 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Praxis Precision Medicines Inc stock has an average upside potential 2026 of . Most analysts recommend the Praxis Precision Medicines Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 8.55 1.47
248.98% 82.81%
EBITDA Margin -2,336.96% -17,466.34%
54.54% 647.40%
Net Margin -2,319.04% -15,377.47%
84.35% 563.10%

10 Analysts have issued a sales forecast Praxis Precision Medicines Inc 2025 . The average Praxis Precision Medicines Inc sales estimate is

$1.5m
Unlock
. This is
82.81% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$8.6m 0.58%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $8.6m 248.98%
2025
$1.5m 82.81%
Unlock
2026
$10.0m 578.12%
Unlock
2027
$44.6m 347.14%
Unlock
2028
$147m 229.93%
Unlock
2029
$392m 166.75%
Unlock

2 Analysts have issued an Praxis Precision Medicines Inc EBITDA forecast 2025. The average Praxis Precision Medicines Inc EBITDA estimate is

$-257m
Unlock
. This is
28.50% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-237m 18.50%
Unlock
, the lowest is
$-277m 38.50%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-200m 58.65%
2025
$-257m 28.50%
Unlock
2026
$-263m 2.47%
Unlock
2027
$-285m 8.26%
Unlock
2028
$-273m 4.27%
Unlock
2029
$-216m 20.83%
Unlock

EBITDA Margin

2024 -2,336.96% 54.54%
2025
-17,466.34% 647.40%
Unlock
2026
-2,639.20% 84.89%
Unlock
2027
-638.97% 75.79%
Unlock
2028
-185.40% 70.98%
Unlock
2029
-55.02% 70.32%
Unlock

5 Praxis Precision Medicines Inc Analysts have issued a net profit forecast 2025. The average Praxis Precision Medicines Inc net profit estimate is

$-226m
Unlock
. This is
13.34% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-206m 3.21%
Unlock
, the lowest is
$-257m 28.92%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-198m 45.37%
2025
$-226m 14.01%
Unlock
2026
$-198m 12.46%
Unlock
2027
$-189m 4.30%
Unlock
2028
$-156m 17.53%
Unlock
2029
$-112m 28.21%
Unlock

Net Margin

2024 -2,319.04% 84.35%
2025
-15,377.47% 563.10%
Unlock
2026
-1,985.09% 87.09%
Unlock
2027
-424.87% 78.60%
Unlock
2028
-106.20% 75.00%
Unlock
2029
-28.58% 73.09%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -10.21 -11.64
45.37% 14.01%
P/E negative
EV/Sales 190.64

5 Analysts have issued a Praxis Precision Medicines Inc forecast for earnings per share. The average Praxis Precision Medicines Inc EPS is

$-11.64
Unlock
. This is
13.34% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-10.60 3.21%
Unlock
, the lowest is
$-13.24 28.92%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-10.21 45.37%
2025
$-11.64 14.01%
Unlock
2026
$-10.19 12.46%
Unlock
2027
$-9.75 4.32%
Unlock
2028
$-8.04 17.54%
Unlock
2029
$-5.77 28.23%
Unlock

P/E ratio

Current -3.24 25.58%
2025
-2.86 11.73%
Unlock
2026
-3.27 14.34%
Unlock
2027
-3.41 4.28%
Unlock
2028
-4.14 21.41%
Unlock
2029
-5.77 39.37%
Unlock

Based on analysts' sales estimates for 2025, the Praxis Precision Medicines Inc stock is valued at an EV/Sales of

190.64
Unlock
and an P/S ratio of
456.76
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 32.78 88.98%
2025
190.64 481.57%
Unlock
2026
28.11 85.25%
Unlock
2027
6.29 77.64%
Unlock
2028
1.91 69.69%
Unlock
2029
0.71 62.51%
Unlock

P/S ratio

Current 78.53 76.18%
2025
456.76 481.63%
Unlock
2026
67.36 85.25%
Unlock
2027
15.06 77.64%
Unlock
2028
4.57 69.69%
Unlock
2029
1.71 62.51%
Unlock

Current Praxis Precision Medicines Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Baird
Locked
Locked
Locked Mar 03 2025
Truist Securities
Locked
Locked
Locked Mar 03 2025
Needham
Locked
Locked
Locked Mar 03 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 03 2025
Deutsche Bank
Locked
Locked
Locked Feb 11 2025
Needham
Locked
Locked
Locked Feb 10 2025
Truist Securities
Locked
Locked
Locked Jan 21 2025
Analyst Rating Date
Locked
Baird:
Locked
Locked
Mar 03 2025
Locked
Truist Securities:
Locked
Locked
Mar 03 2025
Locked
Needham:
Locked
Locked
Mar 03 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 03 2025
Locked
Deutsche Bank:
Locked
Locked
Feb 11 2025
Locked
Needham:
Locked
Locked
Feb 10 2025
Locked
Truist Securities:
Locked
Locked
Jan 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today